CELLTRION PHARM, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92,800 KRW | -1.07% |
|
-4.03% | +0.65% |
| Jan. 16 | Celltrion Holdings Actively Pursuing Nasdaq Listing | MT |
| Jan. 02 | Celltrion's Shares Climb After Merger With Affiliate | DJ |
| Sales 2019 | 174B 127M | Sales 2020 | 234B 171M | Capitalization | 8,705B 6.38B |
|---|---|---|---|---|---|
| Net income 2019 | 8.6B 6.31M | Net income 2020 | 20.94B 15.35M | EV / Sales 2019 | 9.06 x |
| Net Debt 2019 | 149B 109M | Net Debt 2020 | 163B 120M | EV / Sales 2020 | 38 x |
| P/E ratio 2019 |
166
x | P/E ratio 2020 |
417
x | Employees | 328 |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 46.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.07% | ||
| 1 week | -4.03% | ||
| Current month | -3.43% | ||
| 1 month | +3.46% | ||
| 3 months | -7.20% | ||
| 6 months | +9.61% | ||
| Current year | +0.65% |
1 week
92 700.00
99 500.00
1 month
89 900.00100 900.00
Current year
87 700.00133 300.00
1 year
57 714.29133 300.00
3 years
53 523.81158 245.82
5 years
23 556.96236 729.00
10 years
5 962.91236 729.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jeong-Soo Suh
CEO | Chief Executive Officer | 64 | 16-03-27 |
Yu-Jin Jeon
DFI | Director of Finance/CFO | 51 | - |
Jung-Jin Seo
CHM | Chairman | 66 | 09-01-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jung-Jin Seo
CHM | Chairman | 66 | 09-01-22 |
Jeong-Soo Suh
CEO | Chief Executive Officer | 64 | 16-03-27 |
Haeng-Ok Kim
BRD | Director/Board Member | 72 | 14-03-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.75% | 2 M€ | -14.14% | ||
| 0.03% | 15 M€ | +19.58% | ||
| 0.01% | 2,867 M€ | +10.47% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 92,800 | -1.07% | 83,501 |
| 24-05-21 | 93,800 | -0.32% | 87,937 |
| 24-05-20 | 94,100 | -1.77% | 128,078 |
| 24-05-17 | 95,800 | -2.94% | 179,669 |
| 24-05-16 | 98,700 | +2.07% | 84,143 |
End-of-day quote Korea S.E., May 21, 2024
More quotes
Celltrion Pharm Inc is a Korea-based company engaged in the manufacture and sale of pharmaceuticals. The Companyâs products include hepatotonics, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs, circularly system drugs, digestives and stomachic drugs, hormone disease drugs, antibiotics, nutrients, tonics, and other drugs. It also provides ethical drugs and over-the-counter (OTC) drugs. The Company distributes its products in domestic market and overseas markets such as Philippines, Kazakhstan, Cambodia and other Southeast Asia countries.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +0.65% | 2.85B | |
| +20.08% | 22.46B | |
| +18.55% | 15.04B | |
| +18.94% | 13.98B | |
| +56.80% | 13.15B | |
| -10.55% | 6.89B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.66% | 5.71B | |
| +4.00% | 4.69B |
- Stock Market
- Equities
- A068760 Stock
